Ignite Creation Date:
2024-05-05 @ 11:29 AM
Last Modification Date:
2024-10-26 @ 9:08 AM
Study NCT ID:
NCT00057239
Status:
COMPLETED
Last Update Posted:
2010-10-04
First Post:
2003-03-27
Brief Title:
An 8 Week Depression Study In Adults Diagnosed With Major Depressive Disorder
Sponsor:
GlaxoSmithKline
Organization:
GlaxoSmithKline
Study Overview
Official Title:
A Multi-Center Randomized Double-Blind Parallel-Group Placebo-Controlled Fixed-Dose Study Evaluating the Efficacy Safety and Tolerability of Two Doses 20mg and 60mg of a Once-Daily Oral Formulation of GW353162 in Subjects With Major Depressive Disorder for a Treatment Period of Eight Weeks
Status:
COMPLETED
Status Verified Date:
2010-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
A Placebo Controlled Study Evaluating Efficacy Safety and Tolerability of Radafaxine in Patients with Major Depressive Disorder MDD
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None